Eli Lilly (LLY) acquires Centessa for up to $7.8 billion
Published on · Source: cnbc.com
AI Summary
Summarized by AI from the source belowEli Lilly (LLY) announced its acquisition of Centessa Pharmaceuticals in a deal valued up to $7.8 billion, aiming to diversify into sleep disorder treatments. Centessa's lead therapy targets excessive daytime sleepiness and is currently in mid-stage studies. Lilly's offer includes $38 per share in cash, a 37.8% premium, and a contingent value right worth about $1.5 billion. Centessa's shares rose 46% in premarket trading following the announcement, which is set to close in the third quarter.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
LLY stock page and all news →Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
